Zolbetuximab

Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors[1].

Product Specifications

CAS Number

[1496553-00-4]

Product Name Alternative

IMAB362; Claudiximab; GC-182

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zolbetuximab.html

Purity

98.10

Solubility

H2O

Smiles

[Zolbetuximab]

Molecular Weight

(147.09 kDa)

References & Citations

[1]Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10 (1) :1967080.|[2]Türeci Ӧ, et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2018 Nov 10;8 (1) :e1523096. |[3]Zhong W, et al. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Front Immunol. 2022 Jun 28;13:885424.